We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Par Pharmaceuticals has sued the FDA for not granting the company 180 days of marketing exclusivity for its first generic of Takeda Pharmaceutical’s Colcrys, asking a federal court to enjoin the agency from approving any competing generics. Read More
A federal appellate court upheld a district court dismissal of Mylan’s antitrust case against Warner Chilcott and Mayne Pharmaceuticals, which alleged that the name-brand drugmakers modified their acne treatment Doryx to maintain a monopoly on the market. Read More
British drugmaker GlaxoSmithKline will pay $20 million to settle the Security and Exchange Commission’s charges that the company bribed healthcare professionals to boost drug sales in China. Read More
The Department of Justice indicted two executives from separate pharmaceutical companies, alleging that one engaged in a kickback scheme and the other relied on confidential study findings to purchase and sell stock. Read More
The UK’s price watchdog is recommending Bayer’s eye medicine Eylea as a first-line treatment for vision loss due to fluid buildup in the retina, provided the company discounts its price. Read More
Despite significant potential savings in time and money, drug and medical device manufacturers have been slow to embrace continuous manufacturing, an FDA technology official said. Read More
The Indian government has revised its list of essential medicines, removing price caps on dozens of drugs in a number of therapeutic classes. Read More
A federal appeals court rejected Genzyme’s rehearing request in a lawsuit that alleges the Patent Trial and Appeal Board violated protocol when it invalidated the company’s patent covering treatment methods for a rare muscle disease. Read More
The Center for American Progress has unveiled a plan to create a system for health care payers to negotiate prices based on the clinical benefits of a treatment. Read More